BioVie’s Bezisterim Data on Alzheimer’s and Long COVID Set for ACP Meeting
Event summary
- BioVie’s two abstracts on bezisterim (NE3107) accepted for poster presentation at the 2026 ACP Annual Meeting, February 18–22.
- Abstracts cover Alzheimer’s disease and Long COVID, highlighting anti-inflammatory epigenetic modulation and Phase 2 trial baseline data.
- Bezisterim targets neuroinflammation via ERK, NFκB, TNF-α pathways; Phase 3 Alzheimer’s trials ongoing with early cognitive biomarker improvements.
- SUNRISE-PD Parkinson’s study topline results expected mid-2026; ADDRESS-LC Long COVID trial enrolling ~200 patients with data due mid-year.
The big picture
BioVie’s acceptance at the ACP meeting underscores growing interest in bezisterim’s multi-indication potential, particularly as neuroinflammation gains traction as a therapeutic target. The company’s parallel progress in Parkinson’s (SUNRISE-PD) and Long COVID (ADDRESS-LC) trials could broaden its pipeline appeal, though execution risks remain high given the competitive landscape in neurodegenerative therapies.
What we're watching
- Clinical Validation
- Whether bezisterim’s Phase 2 and 3 data can validate its anti-inflammatory mechanism in Alzheimer’s and Long COVID.
- Regulatory Pathway
- The pace at which BioVie advances BIV201 for liver disease through Phase 3 trials, leveraging FDA Fast Track designation.
- Market Differentiation
- How bezisterim’s dual focus on neuroinflammation and insulin sensitivity positions it against competitors in neurodegenerative diseases.
Our editorial coverage: